Odyssey Therapeutics, Inc. priced its initial public offering at $18.00 a share, offering 15,500,000 shares of common stock, to list on the Nasdaq Capital Market under the symbol ODTX. It filed a Form S-1 registration statement for an initial public offering on January 17, 2025. As of November 7, 2026, its final prospectus is on file (Form 424B4, May 8, 2026).
Sell to companies like Odyssey Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Odyssey Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-01-17. It has amended it 1 time. It filed its final prospectus on 2026-05-08, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.
Also on the record for Odyssey Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 13% of the class | 5%+ stakes | Source |
| June 5, 2026 | Stake report, Schedule 13G, by FMR LLC | 10.2% of the class | 5%+ stakes | Source |
| May 18, 2026 | Stake report, Schedule 13D, by SR One Capital Management, LLC | 8% of the class | 5%+ stakes | Source |
| May 18, 2026 | Stake report, Schedule 13D, by TPG GP A, LLC | 7.8% of the class | 5%+ stakes | Source |
| May 18, 2026 | Stake report, Schedule 13G, by Lightspeed Venture Partners XV-B (Ignite), L.P. | 7.6% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13D, by Dimension Capital II, L.P. | 7.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13D, by Jeito II S.L.P. | 7.8% of the class | 5%+ stakes | Source |
| December 4, 2025 | Form D, private offering | $214.03M sold | Form D page | Source |
Check before you invest in Odyssey Therapeutics, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Odyssey Therapeutics, Inc. and the records around it.
The people at Odyssey Therapeutics, Inc.
- Shelley Chu is also named on 1 other Form D filing: Antares Therapeutics, Inc. (May 2025)
Odyssey Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Form D filing Dec 2025
- Who owns it
Companies that share a holder
- SR One Capital Management, LLC also filed stake reports on 6 other companies: ADARx Pharmaceuticals, Inc. (Oct 2026), Zenas BioPharma, Inc. (Aug 2026), Veradermics, Inc. (Aug 2026)
- TPG GP A, LLC also filed stake reports on 15 other companies: Allogene Therapeutics, Inc. (Sep 2026), TPG Inc. (Aug 2026), Ceribell, Inc. (Aug 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Also filing to list on the Nasdaq Capital Market
IPO filings on the Nasdaq Capital Market in Q2 2026, newest first.
- Tenon Medical, Inc. (Jun 2026)
- Exyn Technologies, Inc. (Jun 2026)
- bioAffinity Technologies, Inc. (Jun 2026)
Watch Odyssey Therapeutics, Inc.
Get an email when Odyssey Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Odyssey Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Odyssey Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Odyssey Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
Our common stock has been approved for listing on the Nasdaq Capital Market, or Nasdaq, under the trading symbol “ODTX.”From the 424B4 filed 2026-05-08
Shares offered
This is an initial public offering of shares of common stock of Odyssey Therapeutics, Inc. We are offering 15,500,000 shares of our common stock.From the 424B4 filed 2026-05-08
Offering price
The initial public offering price is $18.00 per share.From the 424B4 filed 2026-05-08
Use of proceeds
We intend to use the net proceeds to us from this offering to (i) advance the clinical development of OD-001, our most advanced product candidate, through 12-week induction readouts from our planned phase 2a combination trial and phase 2b monotherapy trial in ulcerative colitis, (ii) advance our SLC15A4 program through IND-enabling activities and our planned phase 1/2a clinical trial and (iii) fund additional discovery, preclinical and clinical activities for disclosed or future programs, enabling capabilities and for general corporate purposes, working capital and other capital expenditures.From the S-1 filed 2026-04-17
Net loss or income
For the years ended December 31, 2025 and 2024, we reported a net loss of $148.6 million and $129.3 million, respectively.From the S-1/A filed 2026-05-04
Withdrawal
Odyssey Therapeutics, Inc. (the Company ) hereby requests, pursuant to Rule 477 under the Securities Act of 1933, as amended (the Securities Act ), that the U.S. Securities and Exchange Commission (the SEC ) consent to the withdrawal of the Companys Registration Statement on Form S-1 (File No. 333-284332), initially filed with the SEC on January 17, 2025, together with all exhibits and amendments thereto (collectively, the Registration Statement ), as of the date hereof or at the earliest practicable date hereafter.From the RW filed 2025-06-09
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-01-17 | Registration statement filed | S-1 |
| 2025-06-09 | Request to withdraw a registration (Form S-1) | RW |
| 2026-04-17 | Registration statement filed | S-1 |
| 2026-05-04 | Registration statement amended | S-1/A |
| 2026-05-08 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Odyssey Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.